Eledon Pharmaceuticals, Inc. (ELDN) Research

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

Market snapshot

Symbol
ELDN
Price
$3.92
Day change
+5.95%
Market cap
$235.0M
P/E ratio
-5.64x
52-week range
1.35-4.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$5.00

Peer companies

  • Abeona Therapeutics Inc. (ABEO)
  • Achieve Life Sciences, Inc. (ACHV)
  • Allogene Therapeutics, Inc. (ALLO)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Editas Medicine, Inc. (EDIT)
  • Humacyte, Inc. (HUMA)
  • Puma Biotechnology, Inc. (PBYI)
  • Entrada Therapeutics, Inc. (TRDA)

Recent insider activity

  • McBride John S. — M-Exempt (3430 shares) on 2026-01-10
  • McBride John S. — M-Exempt (3430 shares) on 2026-01-10
  • Hillson Jan — M-Exempt (3430 shares) on 2026-01-10
  • Hillson Jan — M-Exempt (3430 shares) on 2026-01-10
  • Kirk Allan — M-Exempt (3430 shares) on 2026-01-10

Open Eledon Pharmaceuticals, Inc. (ELDN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.